Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Fibrocell Science, Inc. was an autologous cell and gene therapy company dedicated to discovering and developing novel treatments for patients with rare and serious skin and connective tissue diseases. Their approach involved using a patient's own cells to create personalized therapies. The company's most notable product candidate was FCX-007 (dibereciclast) for recessive dystrophic epidermolysis bullosa (RDEB) and FCX-013 for localized scleroderma. In late 2019, Fibrocell Science was acquired by Castle Creek Pharmaceuticals (now Castle Creek Biosciences), a company focused on developing and commercializing innovative therapies for rare genetic skin and connective tissue disorders.
The headquarters served as the primary center for Fibrocell's research and development, clinical trial management, and corporate operations, focusing on advancing their gene therapy pipeline.
As a biotech R&D facility, it likely housed specialized laboratories for cell culture, gene vector development, and analytical testing, crucial for their autologous therapy programs.
The work culture at Fibrocell Science was likely characterized by a strong scientific focus, innovation-driven environment, and a patient-centric approach, typical of companies developing treatments for rare diseases.
This location was significant as the hub for Fibrocell's pioneering work in developing personalized cell and gene therapies for debilitating skin conditions before its assets and programs were integrated into Castle Creek Biosciences.
Prior to its acquisition, Fibrocell Science's operations were primarily concentrated in the United States, focusing on research, development, and clinical trials. While they may have collaborated with international research institutions or CROs for specific trial sites, they did not maintain significant independent international offices. Their product candidates were targeted for US regulatory approval initially.
405 Eagleview Blvd
Exton
Pennsylvania
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Fibrocell Science' leadership includes:
Fibrocell Science has been backed by several prominent investors over the years, including:
As Fibrocell Science was acquired by Castle Creek Biosciences in late 2019 and ceased independent operations, there have been no executive hires or exits attributable to Fibrocell Science as an independent entity within the last 12 months. Any leadership changes would have occurred during the acquisition and integration process into Castle Creek Biosciences more than 12 months ago.
Discover the tools Fibrocell Science uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition, Fibrocell Science likely used common corporate email formats. The domain would have been fibrocell.com. Post-acquisition, these email addresses are no longer active.
[first_initial][last]@fibrocell.com
Format
jdoe@fibrocell.com
Example
0 (Company acquired, email domain likely inactive)%
Success rate
GlobeNewswire • December 19, 2019
Castle Creek Pharmaceuticals (now Castle Creek Biosciences) announced the completion of its acquisition of Fibrocell Science, Inc. This acquisition combined Fibrocell's late-stage gene therapy pipeline for rare skin diseases with Castle Creek's expertise in developing and commercializing therapies for dermatologic conditions....more
Fibrocell Science Press Release (via GlobeNewswire) • September 26, 2019
Fibrocell reported positive interim data from its Phase 1/2 clinical trial of FCX-007, an investigational gene therapy for recessive dystrophic epidermolysis bullosa, showing promising wound healing and safety profiles....more
FDA / Company Release • June 22, 2011
Fibrocell Science announced that the U.S. Food and Drug Administration (FDA) approved LAVIV (azficel-T), an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. This marked a significant milestone for the company in bringing an autologous cell therapy to market....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Fibrocell Science, are just a search away.